Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS

Intervention/treatment:
LEVOSIMENDAN
Medical condition:
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Protocol code:
3119002
Control number:
213787
Status:
Closed
Approved:
March 14, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03505021
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 120 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Director, Clinical Operations
Organization
Orion Corporation
Phone:
358104261
Sponsor
ORION CORPORATION

Locations

Alberta

Alberta Health Services - Neuromuscular Clinic
Calgary, Alberta, T3M 1M4
University of Alberta
Edmonton, Alberta, T6G 2G3

New Brunswick

Moncton Hospital, Southeast Regional Health Authority
Moncton, New Brunswick, E1C 2Z3
Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, E3B 0C7

Ontario

McMaster University Medical Centre
Hamilton, Ontario, L8N 3Z5
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5

Quebec

Centre De Recherche Du Centre Hospitalier de l'Universite de Montreal - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1
Centre Hospitalier Affilie Universitaire de Quebec
Québec, Quebec, G1J 1Z4
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4

Results

See the results from the trial NCT03505021. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?